Filing Flows › Vertex Pharmaceuticals (VRTX) › Capital expenditures
Vertex Pharmaceuticals (VRTX) capital expenditures by quarter
Vertex Pharmaceuticals' capital expenditures were $97.3M in Q3 2026 (third quarter 2026), -13% from Q2 2026. Over the last 7 quarters it ranged from $40.7M (Q1 2025) to $149M (Q4 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $97.3M | -13% | -4% |
| Q2 2026 | $112M | -16% | -23% |
| Q1 2026 | $133M | -11% | +228% |
| Q4 2025 | $149M | +47% | — |
| Q3 2025 | $102M | -30% | — |
| Q2 2025 | $146M | +258% | — |
| Q1 2025 | $40.7M | — | — |
Q3 2026 at a glance
Vertex Pharmaceuticals, Q3 2026: revenue $3.4B (+12% year over year), operating margin 20.7%, net earnings $654M, operating cash flow $643M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vertex Pharmaceuticals' capital expenditures?
Vertex Pharmaceuticals' capital expenditures were $97.3M in Q3 2026 (third quarter 2026), -13% from Q2 2026.
How has Vertex Pharmaceuticals' capital expenditures changed?
Over the last 7 quarters it ranged from $40.7M (Q1 2025) to $149M (Q4 2025).
Q3 2026 results → · How Vertex Pharmaceuticals makes money →